While the long-term goals for treatment of COVID-19 include the development of a vaccine that can attenuate the effects of this coronavirus, along with the potential testing and utilization of antivirals that may be effective, there is evidence that the ACE2 pathway can be modulated with existing medications, particularly those along the renin–angiotensin–aldosterone (RAAS) pathway [5,6]. This evidence concerns the gene REN and COVID-19.